H. John Tucker's Insider Trades & SAST Disclosures
H. John Tucker's most recent trade in scPharmaceuticals Inc was a trade of 300,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 11, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern H. John Tucker.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| scPharmaceuticals Inc | John H. Tucker | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| scPharmaceuticals Inc | John H. Tucker | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 200,000 | 440,847 (2%) | 1% | 0 | Common Stock | |
| scPharmaceuticals Inc | John H. Tucker | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.56 per share. | 03 Jan 2025 | 13,360 | 240,847 (1%) | 0% | 3.6 | 47,544 | Common Stock |
| scPharmaceuticals Inc | John H. Tucker | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2024 | 56,025 | 56,025 | - | - | Stock Option (right to buy) | |
| scPharmaceuticals Inc | H. John Tucker | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 170,340 | 170,340 | - | - | Stock Option (right to buy) | |
| scPharmaceuticals Inc | Tucker John H. | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 113,560 | 254,207 (1%) | 0% | 0 | Common Stock | |
| scPharmaceuticals Inc | Tucker H. John | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.39 per share. | 02 Jan 2024 | 4,942 | 140,647 (0%) | 0% | 6.4 | 31,579 | Common Stock |
| scPharmaceuticals Inc | John H. Tucker | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| scPharmaceuticals Inc | John H. Tucker | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 6.14 per share. | 19 Jan 2023 | 66,665 | 145,589 (0%) | 0% | 6.1 | 409,323 | Common Stock |
| scPharmaceuticals Inc | John H. Tucker | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2022 | 42,250 | 42,250 | - | - | Stock Option (right to buy) | |
| scPharmaceuticals Inc | John H. Tucker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Oct 2022 | 42,250 | 89,212 (0%) | 0% | - | Common Stock | |
| scPharmaceuticals Inc | John H. Tucker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Oct 2022 | 42,250 | 0 | - | - | Restricted Stock Units | |
| scPharmaceuticals Inc | John H. Tucker | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.98 per share. | 07 Oct 2022 | 10,288 | 78,924 (0%) | 0% | 5.0 | 51,234 | Common Stock |
| scPharmaceuticals Inc | John H. Tucker | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 249,000 | 249,000 | - | - | Stock Option (Right to Buy) | |
| scPharmaceuticals Inc | John H. Tucker | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 3.96 per share. | 03 Dec 2021 | 10,000 | 46,962 (0%) | 0% | 4.0 | 39,553 | Common Stock |
| scPharmaceuticals Inc | John H. Tucker | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2021 | 112,050 | 112,050 | - | - | Stock Option (Right to Buy) | |
| scPharmaceuticals Inc | John H. Tucker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2020 | 42,250 | 47,250 (0%) | 0% | - | Common Stock | |
| scPharmaceuticals Inc | John H. Tucker | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2020 | 42,250 | 42,250 | - | - | Stock Option (right to buy) | |
| scPharmaceuticals Inc | John H. Tucker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2020 | 42,250 | 0 | - | - | Restricted Stock Units | |
| scPharmaceuticals Inc | John H. Tucker | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.36 per share. | 30 Jun 2020 | 10,288 | 36,962 (0%) | 0% | 7.4 | 75,720 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges